Mary Jo Pilat

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Ejection Fraction

Placebo Controlled

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Kristina A Fanucci, Mary Jo Pilat, Derek Shyr, Yu Shyr, Scott A Boerner, Jing Li, Diane E Durecki, Jan Drappatz, Vinay K Puduvalli, Frank Scott Lieberman, Javier Gonzalez, Pierre Giglio, Susan Percy Ivy, Ranjit S Bindra, Antonio Omuro, Patricia M LoRusso
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2 -mutant Glioma. Cancer research communications 3 (2) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)
Michael Cecchini, Zenta Walther, Wei Wei, Navid Hafez, Mary Jo Pilat, Scott A Boerner, Diane E Durecki, Joseph Paul Eder, Kurt A Schalper, Helen X Chen, Patricia M LoRusso
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer research communications 3 (6) (2023)